Share This:
https://ntp.niehs.nih.gov/go/4963

TDMS Study 88133-06 Pathology Tables

NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02
Route: SKIN APPLICATION                                                                                           Time: 10:08:32

                                                            Final#3




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  15625-89-5

       Lock Date:  06/16/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 002    0 MG/KG
                               Include 001    0 MG/KG
                               Include 004    0.75    MG/KG
                               Include 003    0.75    MG/KG
                               Include 006    1.5     MG/KG
                               Include 005    1.5     MG/KG
                               Include 008    3 MG/KG
                               Include 007    3 MG/KG
                               Include 010    6 MG/KG
                               Include 009    6 MG/KG
                               Include 012    12 MG/KG
                               Include 011    12 MG/KG























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                                   1            2            1            1            3           
    Moribund Sacrifice                                                           1                                                  
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           14           12           14           14           12           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
   Salivary Glands                                    (1)                                                              (1)          
      Carcinoma                                        1 (100%)                                                                     
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          3 (20%)      4 (27%)      3 (20%)      1 (7%)       4 (27%)      6 (40%)     
      Squamous Cell Papilloma, Multiple                1 (7%)       1 (7%)       1 (7%)       1 (7%)       1 (7%)       3 (20%)     
   Tooth                                              (1)          (4)          (3)          (1)          (3)          (2)          
      Odontogenic Tumor                                1 (100%)     4 (100%)     2 (67%)                   3 (100%)     1 (50%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Pituitary Gland                                    (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)         (15)         
   Uterus                                             (15)         (15)         (15)         (15)         (15)         (15)         
   Vagina                                                          (1)                                                              
      Squamous Cell Papilloma                                       1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (11)         (14)         (13)         (10)         (13)         (12)         
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)         (15)         
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (15)         
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
   Thymus                                             (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                                       1 (7%)                    1 (7%)                                
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                              1 (7%)                    1 (7%)       1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           1 (7%)       6 (40%)                  
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                              5 (33%)     15 (100%)    
      Vulva, Squamous Cell Papilloma                                                                       1 (7%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                                            (1)                                                              
      Osteosarcoma                                                  1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Alveolar/Bronchiolar Adenoma                     1 (7%)                                 1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                         1 (7%)                    1 (7%)                    2 (13%)     
      Lymphoma Malignant                                                                                                1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS FEMALE            0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             6           9           6           5          12          15               
     Total Primary Neoplasms                            7          13           7           6          21          29               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           5           4           4          11          15               
     Total Benign Neoplasms                             5           7           4           5          17          24               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           2           1           1           1           3               
     Total Malignant Neoplasms                          1           2           1           1           1           4               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  1           4           2                       3           1               
     Total Uncertain Neoplasms                          1           4           2                       3           1               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      1                         3            1            2            4           
  Survivors                                                                                                                         
    Terminal Sacrifice                                14           15           12           14           13           11           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
   Salivary Glands                                                              (1)          (1)                       (2)          
      Carcinoma                                                                  1 (100%)     1 (100%)                  1 (50%)     
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          3 (20%)      4 (27%)      1 (7%)       2 (13%)      2 (13%)      2 (13%)     
      Squamous Cell Papilloma, Multiple                2 (13%)      3 (20%)                   2 (13%)      1 (7%)                   
   Tooth                                              (1)          (3)          (1)          (2)          (1)          (1)          
      Odontogenic Tumor                                1 (100%)     3 (100%)     1 (100%)                  1 (100%)     1 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Pituitary Gland                                    (15)         (15)         (15)         (14)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (13)         (13)         (14)         (15)         (14)         (14)         
   Lymph Node, Mandibular                             (15)         (14)         (15)         (15)         (14)         (13)         
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (12)         
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
   Thymus                                             (15)         (15)         (14)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                                                                                           2 (13%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           2 (13%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                             12 (80%)     13 (87%)     
      Subcutaneous Tissue, Fibrosarcoma                                          1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (14)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 88133-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK                          TRIMETHYLOLPROPANE TRIACRYLATE                              Date: 10/30/02  
Route: SKIN APPLICATION                                                                                           Time: 10:08:32  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TGAC (FVB/N) HEMIZYGOUS MALE              0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             6           8           4           6          12          13               
     Total Primary Neoplasms                            6          10           4           8          16          20               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           7           1           5          12          13               
     Total Benign Neoplasms                             5           7           1           6          15          17               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       2           1                       2               
     Total Malignant Neoplasms                                                  2           2                       2               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  1           3           1                       1           1               
     Total Uncertain Neoplasms                          1           3           1                       1           1               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------